A rational framework for decision making by the National Institute For Clinical Excellence (NICE)

Lancet

Volumn 360, Issue 9334, 2002, Pages 711-715

  Claxton, Karl ^a   Sculpher, Mark ^a   Drummond, Michael ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL;

ALZHEIMER DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG EFFICACY; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE SYSTEM; HEALTH SERVICE; HUMAN; MEDICAL RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; REIMBURSEMENT; REVIEW; TECHNOLOGY;

EID: 0037206042     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)09832-X     Document Type: Note

References (22)

1. Commonwealth Department of Health, Housing and Community Services . Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee. 1992;AGPS, Canberra.
2. Ministry of Health . Ontario Guidelines for Economic Analysis of Pharmaceutical Products. 1994;Ministry of Health, Ontario.
3. Langley P.C. Formulary submission guidelines for Blue Cross and Blue Shield of Colorado and Nevada: structure, application and manufacturer responsibilities. Pharmacoeconomics. 16:1999;211-224.
4. Song F., O'Meara S., Wilson P., et al. The effectiveness and cost-effectiveness of prophylactic removal of wisdom teeth. Health Technol Assess. 4:2000;1-55.
5. Drummond M.F., Davies L. Economic analysis alongside clinical trials. Int J Technol Assess Health Care. 7:1991;561-573.
6. McDonagh M.S., Bachmann L.M., Golder S., et al. A rapid and systematic review of the clinical effectiveness of glycoprotein IIb/IIa antagonists in the medical management of unstable angina. Health Technol Assess. 4:2000;1-95.
7. Sculpher M.J., Drummond M.F., Buxton M.J. The iterative use of economic evaluation as part of the process of health technology assessment. J Health Serv Res Policy. 2:1997;26-30.
8. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ. 18:1999;342-364.
9. Briggs A., Sculpher M.J. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 13:1998;397-409.
10. Neumann P.J., Hermann R.C., Kuntz K.M. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology. 52:1999;1138-1145.
11. Clegg A., Bryant J., Nicholson T., et al. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. Health Technol Assess. 5:2000;1-137.
12. Sonnenberg F.A., Beck J.R. Markov models in medical decision making. Med Decis Making. 13:1993;322-338.
13. Sherlaw-Johnson A. Cytological screening and management of abnormalities in prevention of cervical canser: and overview with stochastic modelling. J Clin Pathol. 47:1994;430-435.
14. Fitzpatrick R., Shortall E., Sculpher M., et al. Primary total hip replacement surgery: a systematic review of outcomes and modelling of cost-effectiveness associated with different prostheses. Health Technol Assess. 2:1998;1-64.
15. Critchfield G.C., Willard K.E. Probabilistic analysis of decision trees using Monte Carlo simulation. Med Decis Making. 6:1986;85-92.
16. Fenwick E., Claxton K., Sculpher M., Briggs A. Improving the efficiency and relevance of health technology assessment: the role of decision analytic modelling (Centre for Health Economics discussion paper 179). 2000;Centre for Health Economics, University of York, York.
17. Claxton K., Neuman P.J., Araki S.S., et al. The value of information: an application to a policy model of Alzheimer's disease. Int J Technol Assess Health Care. 17:2001;38-55.
18. Claxton K., Posnett J. An economic approach to clinical trial design and research priority-setting. Health Econ. 5:1996;513-524.
19. Felli J.C., Hazen G.B. Sensitivity analysis and the expected value of perfect information. Med Decis Making. 18:1998;95-109.
20. Thompson K.M., Evans J.S. The value of improved national exposure information for perchloroethylene (perc): a case study for dry cleaners. Risk Anal. 17:1997;253-271.
21. Claxton K., Neumann P., Araki S., et al. The efficient design of clinical trials: an application to the evaluation of treatment strategies for Alzheimer's disease. Med Decis Making. 19:1999;4. abstr.
22. Neumann P.J., Claxton K., Weinstein M.C. The FDA's regulation of health economic information. Health Aff. 19:2000;129-137.